Singapore Sleeping Pills Market Size & Outlook, 2025-2033
Singapore Sleeping Pills Market Insights
- Based on Reed Intelligence findings, the Singapore Sleeping Pills Market reached USD 522.84 Million in 2024 and is estimated to attain USD 861.17 Million by 2033.
- From 2025 to 2033, the Singapore market is expected to grow at a steady CAGR of 5.72%.
- Within the By Product Type category, Benzodiazepines dominated in 2024 in terms of market size contribution.
- Over the forecast period, Non-Benzodiazepines is forecasted to deliver the fastest growth, positioning it as the most lucrative By Product Type segment.
Source: RI Analysis Company Publications, Primary Interviews.
Other Key Findings
- In 2024, Singapore accounted for 0.6% of the global Sleeping Pills Market size.
- By 2033, United States is expected to lead the global Sleeping Pills Market in terms of market size.
- Within Asia Pacific, China is projected to dominate the regional Sleeping Pills Market size by 2033.
- Australia is identified as the fastest-growing market in Asia Pacific, anticipated to reach USD 2189.72 Million by 2033.
Report Summary
| Report Scope | Details |
|---|---|
| Base Year for Study | 2024 |
| Study Period | 2021-2033 |
| Historical Period | 2021-2023 |
| Forecast Period | 2025-2033 |
| Market Size In 2024 | USD 522.84 Million |
| Market Size In 2033 | USD 861.17 Million |
| Largest segment | Benzodiazepines |
| Units | Revenue in USD Million |
| CAGR | 5.72% (2025-2033) |
| Segmnetation Covered | |
| By Product Type |
|
| By Use |
|
| By Sleep Disorder |
|
| By Distribution Channel |
|
| Report Coverage | Revenue Forecast, Competitive Landscape, Growth Factors, Environment & Regulatory Landscape and Trends |
Singapore Sleeping Pills Market By Product Type 2025-2033 (USD Million)
| By Product Type | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Benzodiazepines | XX.x | XX.x | XX.x | 293.73 | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Non-Benzodiazepines | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Total | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
Source: RI Analysis Company Publications, Primary Interviews.
Singapore Sleeping Pills Market By Use 2025-2033 (USD Million)
| By Use | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Short-term Use | XX.x | XX.x | XX.x | 329.81 | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Long-term Use | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Total | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
Source: RI Analysis Company Publications, Primary Interviews.
Singapore Sleeping Pills Market By Sleep Disorder 2025-2033 (USD Million)
| By Sleep Disorder | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Insomnia | XX.x | XX.x | XX.x | 231.15 | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Sleep disorder | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Restless leg syndrome narcolepsy | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Sleepwalking | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Total | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
Source: RI Analysis Company Publications, Primary Interviews.
Singapore Sleeping Pills Market By Distribution Channel 2025-2033 (USD Million)
| By Distribution Channel | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Hospital Pharmacies | XX.x | XX.x | XX.x | 270.1 | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Retail Pharmacies and Drug Stores | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Online Pharmacies | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Total | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
Source: RI Analysis Company Publications, Primary Interviews.
